Lanean...
Cachectic Cancer Patients: Immune to Check-point Inhibitor Therapy?
Immune check-point inhibition is dramatically improving patient outcomes in diverse cancers, many of which responded poorly to traditional cytotoxic agents. Drivers of heterogeneous response to immune check-point therapy are poorly characterized. Cachectic cancer patients exhibit elevated pembrolizu...
Gorde:
| Argitaratua izan da: | Clin Cancer Res |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6279566/ https://ncbi.nlm.nih.gov/pubmed/30018117 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1847 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|